
HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ:BNTX) while reducing the price target to $298 from the prior $339.
The analyst noted initial data of BNT211, an autologous CAR-T cell therapy, shared at the American Association for Cancer Research (AACR) meeting.